Nubeqa, a prostate cancer treatment, can be prescribed at general hospitals. According to related industries, Bayer Korea's oral androgen receptor inhibitor (ARi) Nubeqa for nmCRPC treatment passed the DC of medical institutions such as Samsung Medical Center, Seoul National University Hospital, Seoul Asan Hospital, and Sinchon Severance Hospital. Nubeqa has not yet been covered by insurance benefits, so it is expected to take time to lead to actual prescription activation.

The drug has not been registered since the HIRA Cancer Disease Review Committee ruled it failed in February 2021. Nubeqa is an androgen receptor inhibitor with a unique chemical structure that binds to androgen receptors to inhibit t